Haisco Pharmaceutical Group Co. Ltd. has identified molecular glue degraders targeting protein cereblon (CRBN) acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.